News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
592,261 Results
Type
Article (40347)
Company Profile (93)
Press Release (551818)
Multimedia
Podcasts (134)
Webinars (23)
Section
Business (175082)
Career Advice (2197)
Deals (28854)
Drug Delivery (105)
Drug Development (62200)
Employer Resources (150)
FDA (14127)
Job Trends (12686)
News (286663)
Policy (27301)
Tag
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2208)
Academic (1)
Accelerated approval (22)
Adcomms (21)
Allergies (112)
Alliances (45166)
ALS (141)
Alzheimer's disease (1414)
Antibody-drug conjugate (ADC) (231)
Approvals (14377)
Artificial intelligence (483)
Autoimmune disease (121)
Automation (30)
Bankruptcy (268)
Best Places to Work (9938)
BIOSECURE Act (15)
Biosimilars (153)
Biotechnology (67)
Bladder cancer (133)
Brain cancer (45)
Breast cancer (545)
Cancer (4018)
Cardiovascular disease (334)
Career advice (1876)
Career pathing (33)
CAR-T (229)
CDC (58)
Celiac Disease (1)
Cell therapy (627)
Cervical cancer (29)
Clinical research (52605)
Collaboration (1527)
Company closure (5)
Compensation (552)
Complete response letters (36)
COVID-19 (2782)
CRISPR (76)
C-suite (679)
Cystic fibrosis (111)
Data (5120)
Decentralized trials (2)
Denatured (41)
Depression (119)
Diabetes (418)
Diagnostics (6832)
Digital health (35)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (218)
Drug pricing (166)
Drug shortages (27)
Duchenne muscular dystrophy (182)
Earnings (76691)
Editorial (58)
Employer branding (20)
Employer resources (136)
Events (89528)
Executive appointments (830)
FDA (16695)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (6)
Frontotemporal dementia (21)
Funding (1199)
Gene editing (156)
Generative AI (48)
Gene therapy (510)
GLP-1 (820)
Government (4211)
Grass and pollen (6)
Guidances (361)
Healthcare (15562)
HIV (50)
Huntington's disease (35)
IgA nephropathy (63)
Immunology and inflammation (202)
Immuno-oncology (46)
Indications (89)
Infectious disease (3044)
Inflammatory bowel disease (151)
Inflation Reduction Act (15)
Influenza (114)
Intellectual property (185)
Interviews (400)
IPO (13137)
IRA (45)
Job creations (3089)
Job search strategy (1552)
JPM (58)
Kidney cancer (12)
Labor market (66)
Layoffs (472)
Leadership (34)
Legal (6756)
Liver cancer (73)
Longevity (11)
Lung cancer (527)
Lymphoma (312)
Machine learning (34)
Management (52)
Manufacturing (681)
MASH (142)
Medical device (10934)
Medtech (10976)
Mergers & acquisitions (16619)
Metabolic disorders (1033)
Multiple sclerosis (134)
NASH (15)
Neurodegenerative disease (272)
Neuropsychiatric disorders (70)
Neuroscience (2414)
NextGen: Class of 2026 (5271)
Non-profit (3822)
Now hiring (40)
Obesity (466)
Opinion (291)
Ovarian cancer (141)
Pain (153)
Pancreatic cancer (180)
Parkinson's disease (224)
Partnered (30)
Patents (379)
Patient recruitment (339)
Peanut (46)
People (49096)
Pharmaceutical (23)
Pharmacy benefit managers (22)
Phase 1 (16203)
Phase 2 (22639)
Phase 3 (18270)
Pipeline (4483)
Policy (272)
Postmarket research (2181)
Preclinical (6873)
Press Release (70)
Prostate cancer (233)
Psychedelics (39)
Radiopharmaceuticals (262)
Rare diseases (692)
Real estate (4900)
Recruiting (60)
Regulatory (19981)
Reports (37)
Research institute (2057)
Resumes & cover letters (338)
Rett syndrome (26)
RNA editing (15)
RSV (82)
Schizophrenia (127)
Series A (197)
Series B (150)
Service/supplier (5)
Sickle cell disease (80)
Special edition (22)
Spinal muscular atrophy (128)
Sponsored (42)
Startups (2909)
State (1)
Stomach cancer (13)
Supply chain (83)
Tariffs (78)
The Weekly (91)
Vaccines (1143)
Venture capital (73)
Weight loss (306)
Women's health (69)
Worklife (17)
Date
Today (81)
Last 7 days (431)
Last 30 days (2034)
Last 365 days (25119)
2026 (2066)
2025 (25379)
2024 (28639)
2023 (32567)
2022 (42848)
2021 (46331)
2020 (45275)
2019 (38438)
2018 (28965)
2017 (27347)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (852)
Alabama (75)
Alaska (6)
Arizona (230)
Arkansas (9)
Asia (33902)
Australia (5900)
California (8712)
Canada (2654)
China (826)
Colorado (404)
Connecticut (417)
Delaware (256)
Europe (80676)
Florida (1349)
Georgia (296)
Hawaii (1)
Idaho (43)
Illinois (676)
India (61)
Indiana (427)
Iowa (19)
Japan (372)
Kansas (103)
Kentucky (35)
Louisiana (18)
Maine (80)
Maryland (1138)
Massachusetts (6333)
Michigan (311)
Minnesota (460)
Mississippi (4)
Missouri (99)
Montana (29)
Nebraska (21)
Nevada (109)
New Hampshire (64)
New Jersey (2590)
New Mexico (28)
New York (2377)
North Carolina (1195)
North Dakota (9)
Northern California (4216)
Ohio (276)
Oklahoma (19)
Oregon (31)
Pennsylvania (1752)
Puerto Rico (9)
Rhode Island (37)
South America (1064)
South Carolina (43)
Southern California (3428)
Tennessee (145)
Texas (1404)
United States (31856)
Utah (299)
Vermont (1)
Virginia (219)
Washington D.C. (70)
Washington State (714)
West Virginia (4)
Wisconsin (104)
Wyoming (2)
592,261 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
obesity
JPM26: Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos
Speaking to
BioSpace
at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss pharma hasn’t acquired a GLP-1, and why it probably won’t.
January 13, 2026
·
3 min read
·
Annalee Armstrong
Radiopharmaceuticals
Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed
While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.
November 6, 2025
·
5 min read
·
Annalee Armstrong
Alzheimer’s disease
Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro
The deal will see Novartis gain global rights over SciNeuro’s potentially disease-modifying anti-amyloid antibody, which leverages the latter’s proprietary shuttle platform to allow delivery into the brain.
January 12, 2026
·
2 min read
·
Tristan Manalac
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Layoffs
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs
Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s disease continue to advance.
December 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development
January 29, 2026
·
2 min read
Press Releases
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
February 3, 2026
·
5 min read
Vaccines
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
January 14, 2026
·
3 min read
·
Annalee Armstrong
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech’s shares flying.
December 9, 2025
·
3 min read
·
Annalee Armstrong
IPO
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.
February 4, 2026
·
11 min read
·
Tristan Manalac
1 of 59,227
Next
